In the technology evaluation First approved inhaled insulin therapy for diabetes mellitus, published in the January 2007 issue of Expert Opinion on Drug Delivery (Expert Opin. Drug Deliv. (2007) 4(1):63-76), the following error has been bought to our attention.
Page 68, section 4.1: the sentence ‘If the repeat value remains ≤ 20%, EXUBERA should be discontinued’ should read ‘If the repeat value remains ≥ 20%, EXUBERA should be discontinued’.